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it is necessary to dissociate the contributions of DS and AD from overall phenotype. Imaging bio-
markers offer the potential to characterize and stratify patients who will worsen clinically but have
yielded mixed findings in DS subjects.
Methods: We evaluated 18F fluorodeoxyglucose positron emission tomography (PET), florbetapir
PET, and structural magnetic resonance (sMR) image data from 12 nondemented DS adults using
advanced multivariate machine learning methods.
Results: Our results showed distinctive patterns of glucose metabolism and brain volume enabling
dissociation of DS and AD effects. AD-like pattern expression corresponded to amyloid burden
and clinical measures.
Discussion: These findings lay groundwork to enable AD clinical trials with characterization and
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Down syndrome (DS) is associated with an increased rate
of Alzheimer’s-like dementia, prevalent in up to 55% of
individuals in their forties and 77% of age .60 years [1].
Neuritic plaques and neurofibrillary tangles consistent with
Alzheimer’s disease (AD) have been identified in nearly all
DS adults examined of age .40 years [1,2]. Because of
this, DS adults may provide a naturally enriched populationlzheimer’s Association. This is an open access article under the CCBY-NC-
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candidates to prevent AD progression. Ideally, trials would
initiate treatment at a common, well-defined point before
AD dementia [2]. This would require individual characteriza-
tion of the degree of AD-related pathology and neurodegen-
eration distinct from DS effects. Detection of disease-
modifying treatment effects would require distinguishing
impact on AD-related pathology from that on underlying DS.
The primary objectives of our work were to: (a) dissociate
within DS subjects the effects attributable to DS versus those
associated with AD, and (b) to quantify the degree of AD
progression. To pursue this, we applied multivariate analysis
advances to baseline 18F fluorodeoxyglucose (FDG) PET
structural magnetic resonance imaging (MRI) images and
examined relationships with amyloid and clinical endpoints.
We hypothesized that nondemented DS subjects with
emerging AD would exhibit a pattern of neurodegeneration
characteristic of prodromal AD. We postulated that standard
image analysis methods might not be able to fully dissociate
effects attributable to DS vs AD within subjects, and that
multivariate analysis software capable of identifying
different contributing networks or patterns to overall effect
could isolate DS and AD components.
The source of DS data for our work was a 3-year DS
Biomarker Initiative (DSBI) study was initiated by Janssen
Research and Development in collaboration with the Univer-
sity of California San Diego (UCSD) and the Alzheimer’s
Disease Cooperative Study (ADCS). This study was de-
signed to demonstrate methodology feasibility for a larger
natural history trial. Endpoints include neuropsychological
testing, positron emission tomography (PET) imaging of ce-
rebral amyloid and glucose metabolism, MRI, and blood
biomarkers [2,3].
In AD, a characteristic pattern of glucose hypometabo-
lism emerges in hippocampus and posterior cingulate, ex-
pands to temporo-parietal regions, and gradually affects
most cortical tissue, whereas pons, cerebellum, and motor
and visual cortices are relatively preserved [4–6]. Changes
are found in genetically at-risk individuals [7,8], begin
years before symptom onset [9], and correlate with clin-
ical decline [4,10]. In DS, results of FDG PET studies
have been mixed [11]. Some studies in young adults
(,25 years) have found no differences or only hyperme-
tabolism compared to normals [12–14]. Other studies in
DS adults have found hypometabolism in AD-relevant re-
gions, more pronounced in demented than nondemented
subjects [15–17]. Findings have not dissociated DS from
AD effects within-subject nor quantified degree of AD
progression.
AD also causes structural atrophy that initiates in entorhi-
nal cortex, spreads to hippocampus, and expands to parietal
and most cortical and subcortical structures [18–20],
correlating with clinical progression [21,22]. In young DS
persons (ages 5 to 23 years), MRI studies have shown
reduced brain volume, shortened frontal lobes, reductions
in cerebellum and brainstem, hippocampus, amygdala, andwhite matter but preservation of parietal and subcortical
regions [23–25]. Studies in DS adults have found lower
volumes overall and in cerebellum, cingulate gyrus, frontal
lobe, superior temporal lobes, and hippocampi and
associations between dementia, regional atrophy typical of
AD, and ventricular enlargement [17,26–30]. However,
structural effects of DS have not been dissociated within
subject from those attributable to AD.
Consistent with postmortem findings, amyloid imaging
studies in DS adults have found a high prevalence of AD-
like amyloid associated with age and dementia [17,31–34].
Our work builds on these findings by differentiating, at the
subject level, the effects attributable to DS independent of
amyloid burden from those associated with emerging AD,
and furthermore, provides a quantitative measure of the de-
gree of AD progression. We demonstrate that these measures
correlate with amyloid and clinical endpoints at baseline.2. Methods
2.1. Subject selection
Twelve nondemented adult individuals diagnosed with
DS, age 32–61 years, were enrolled. Exclusion of a diag-
nosis of dementia was based on absence of evidence of
recent deterioration in cognitive function not secondary to
medical illness (e.g., hypothyroidism, sleep apnea) or mental
illness (e.g., depression), with absence of a significant
decline in function over a period of 6 months or more. The
diagnosing neurologist was experienced with premorbid def-
icits in DS and incorporated dementia diagnosis recommen-
dations from the National Task Group on Intellectual
Disabilities and Dementia Practices [35]. Ten subjects
were female; six were APOE ε4 carriers. Assessments
were conducted by UCSD in collaboration with the ADCS
under IRB-approved protocols with patient informed
consent [3].
2.2. Image data acquisition, processing, and analysis
All subjects received FDG PET, florbetapir (amyloid)
PET, and structural MRI (sMRI) scans, acquired and pro-
cessed as described in the Supplementary Material and [3].
FDG PET and MRI analyses were performed while blinded
to amyloid, APOE ε4, and clinical status. Image analysis
consisted of three parallel, complementary approaches.
2.2.1. Analyses with NPAIRS
The NPAIRS [36,37] multivariate analysis software
framework was applied to detect patterns in FDG PET and
T1-weighted sMRI characterizing similarities and differ-
ences between the DS group and pre-defined comparator
groups. In brief, NPAIRS uses canonical variates analysis
(a form of linear discriminant analysis) to identify uncorre-
lated spatial patterns that when mathematically combined
account for overall variance across groups of image data.
Importantly, NPAIRS uses an iterative resampling process
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lation between the model generated by each split half) and
prediction (correct classification of the test half using the
training half model) are used to optimize the model. This
process addresses the issue of over-fitting that can arise in
machine learning, particularly when data sets are small. A
canonical variate (CV) score quantifies the degree to which
each subject expresses each pattern. The test (rather than
training) scores were used to report results.
For comparison to DS subjects in the NPAIRS analysis,
four sets of 12 subjects (balancing N) were identified a priori
from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database based on ADNI clinical diagnosis, amyloid
status, and age: amyloid negative (Am2) normal (NL), am-
yloid positive (Am1) AD, Am1 early mild cognitive
impairment (EMCI), and Am1 late MCI (LMCI). The
ADNI database (adni.loni.usc.edu) was launched in 2003
as a public–private partnership, led by Principal Investigator
Michael Weiner MD, with the goal to test whether serial
MRI, PET, other biological markers, and clinical and neuro-
psychological assessment can be combined to measure the
progression of MCI and early AD (see www.adni-info.
org). As DS FDG and MRI scans were acquired using
ADNI protocols and processed in the same manner, compar-
ison was feasible. Subjects were considered Am2 if their
amyloid PET cortical average standardized uptake value ra-
tio (SUVR) was below a threshold of 1.47 for 11C-PiB [38]
or ,1.11 for florbetapir [39] or their cerebrospinal fluid
(CSF) Abeta42 was .209 (allowing for threshold vari-
ability) and were considered Am1 if their amyloid PET
SUVR exceeded threshold or their CSF Abeta42 level was
,192 [40]. Given the relatively young DS subject ages,
the youngest ADNI subjects meeting diagnostic and amyloid
criteria were selected.
Three models using different combinations of classes
were explored in NPAIRS using FDG PET, and the first
was also explored using MRI: (1) DS, NL, AD; (2) DS,
NL, AD, EMCI, LMCI; and (3) DS, NL. For each model
of N classes, NPAIRS produced N-1 patterns and CV scores
for each subject that quantified expression of each pattern.
In addition, because ADNI subjects were still somewhat
older than most DS subjects, twelve age-matched, Am2,
cognitively normal subjects (AE-NL) with FDG PET scans
acquired at New York University [41] were selected for
additional comparison in a four-class model of DS, NL,
AD, and AE-NL. The purpose was to determine whether
differences between DS and NL were consistent with
that between DS and AE-NL. Acquisition parameters for
these subjects were consistent with ADNI, and their pro-
cessing parameters were sufficiently similar to enable
confirmatory comparison as described in Results and
shown in the Supplementary Material, but owing to other
processing differences, they were not used as primary com-
parators. These differences included increased smoothing
and the extent of superior slices in some scans, which
were reconciled with additional smoothing and maskingfor analysis. The use of NYU subjects also helped to test
for site differences.
Furthermore, because all DS scans but none of the
comparator subjects came from a single site and scanner,
an additional set of twelve ADNI subjects ranging in status
from Am2 NL to Am1 AD and having FDG PET scans ac-
quired from the same site and scanner as the DS subjects
were selected for comparison (SITE1 class). These subjects
had not been selected as primary comparators because
younger ADNI subjects were available. A model consisting
of DS, NL, AD, and SITE1 was evaluated using NPAIRS to
assess potential site differences, and ROI values of the
SITE1 NL subjects were also compared to NL and DS.
2.2.2. AD progression classifier scoring
Each DS FDG PET scan was scored using our AD pro-
gression classifier. This algorithm, previously developed us-
ing machine learning and 166 subjects from ADNI
characterized by clinical diagnosis, amyloid status, and lon-
gitudinal outcome, assigns a numeric score reflecting the de-
gree to which the subject’s scan expresses a pattern of
hypometabolism and hypermetabolism relative to whole
brain associated with AD progression [42] (See
Supplementary Material and Supplementary Fig. 1 for
further description.) DS CV scores were compared to
mean scores previously derived from ADNI subjects at
stages from Am2 NL to Am1 AD.
2.2.3. Region of interest analyses
A priori AD-relevant regions of interest (ROIs) [43] were
measured on the FDG scans, and SUVRs calculated.
Primary regions of interest were posterior cingulate-
precuneus (PCC) and inferior parietal cortex (IPL). Hippo-
campus, medial temporal gyrus (MTL; including hippocam-
pus), lateral temporal cortex, and middle frontal gyrus were
also examined. Whole brain without ventricles was used as
the primary reference region, and SUVRs were compared
using pons as an alternate reference region to further under-
stand regional differences.
Once unblinded to amyloid data, each DS subject’s amy-
loid cortical average SUVR was measured by averaging
anterior cingulate, posterior cingulate, precuneus, lateral
temporal, frontal, and inferior parietal regions, referenced
to whole cerebellum. SUVRs were also calculated using
pons and subcortical white matter as alternate reference re-
gions for comparison, to confirm the absence of artifact in
the primary reference region due to subject motion or tech-
nical factors during image acquisition.2.3. Statistical analyses
Each NPAIRS analysis, through iterative split-half re-
sampling, generated measures of reproducibility (correlation
between the trainingmodel for each split half) and predictive
power (correct classification of test split half using model
developed by training split half) indicating whether results
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normality and homogeneity of variance (Levene test),
compared using nonparametric tests (Wilcoxon–Mann–
Whitney) as the sample sizes were 12 or less per group,
and effect sizes (ES) were calculated. In cases where all
groups had at least 12 subjects and other criteria for para-
metric analyses were satisfied, parametric t tests were also
performed for comparison. FDG PET ROI values for PCC
and IPL referenced to whole brain were compared using
nonparametric tests (Wilcoxon–Mann–Whitney) between
the NL group and DS Am2, DS Am1, EMCI, LMCI, and
AD groups, with and without age correction, and after
applying a Bonferroni correction for multiple comparisons.
Correlation coefficients (nonparametric Spearman’s R)
were measured for FDG AD Progression scores, FDG CV
scores, and sMRI CV scores vs age, amyloid SUVR, and
baseline clinical measures; amyloid SUVRs vs baseline clin-
ical measures; and sMRI-CV2 scores vs FDG AD Progres-
sion scores and CV2FDG scores.3. Results
Subject demographics and DS participant clinical scores
are shown in Table 1.
3.1. Amyloid status
Three DS subjects were Am2 as measured using florbe-
tapir PET, one was at threshold for positivity, and eight were
Am1. Of the four Am2 and threshold DS subjects, three
were APOE ε3/ε3, and one (Am2) was 2/4. Five (62%) of
the Am 1 subjects were heterozygous carriers (3/4) and
three were non-carriers. Results referenced to whole cere-
bellum were consistent with those referenced to pons and
subcortical white matter (Supplementary Fig. 2).Table 1
Subject demographics
Variable DS NL EMCI LMCI AD AE-NL
Number 12 12 12 12 12 12
Age [Mean (SD)] 45 (8.5) 63 (2.5) 67 (2.1) 57 (3.2) 58 (2.5) 45 (8.5)
Gender (% F) 83 67 33 42 58 75
Education (y) 13 (5.1) 17 (2.0) 15 (2.6) 17 (2.5) 16 (2.7) n/a
APOE ε4
carrier (%)
50 17 92 67 67 n/a
Amyloid pos (%) 58* 0 100 100 100 0
Vineland measures for DS subjects (adjusted to mental, rather than
chronological, age)
Receptive 12.58 (3.65) Expressive 12.83 (3.74)
Written 15.73 (5.00) Personal 14.58 (4.08)
Domestic 18.09 (3.45) Community 15.67 (4.40)
Interpersonal
relationships
15.50 (3.63) Play and leisure
time
12.67 (5.48)
Coping skills 17.33 (3.23)
*DS amyloid burden as measured during analysis; negative includes one
subject at or just below threshold depending on the reference region
applied.3.2. FDG NPAIRS comparisons
Results of the NPAIRS 3-class comparison of DS, NL,
and AD are shown in Fig. 1. Two distinct glucose meta-
bolism patterns with partial overlap were identified, each
having reproducibility and prediction metrics indicating
generalizability to a broader population (as did all patterns
discussed). The first pattern (Fig. 1A, CV1FDG) differenti-
ated DS from NL (P , .00001, effect size (ES) 5.94) and
AD (P, .00001, ES 6.58). There was no separation between
Am2 and Am1 DS subjects (CV1FDG plot, Fig. 1A). This
pattern did not correlate with age. The second (Fig. 1B,
CV2FDG) separated NL from AD (P , .00001, ES 3.48),
whereas DS scores were distributed across the range from
NL to AD. All Am2 or threshold subjects had CV2FDG
scores in the range of NL. CV2FDG correlated with age in
DS subjects (R 5 0.659, P , .02). (Results were consistent
using both parametric and nonparametric tests.)
In the DS-associated pattern CV1FDG, hypometabolism
was observed in posterior cingulate, anterior cingulate, precu-
neus (particularly anterior), paracentral lobule, postcentral
gyrus/supplementary motor cortex, superior temporal cortex,
hippocampus, striatum, insula, and inferior frontal cortex.
Relative hypermetabolism was found in frontal cortex, supe-
rior temporal gyrus, and occipital cortex. Pattern features are
relative to brain mean; therefore, hypermetabolism or volume
increases can also be interpreted as relative preservation.
The CV2FDG pattern (Fig. 1B) was characterized by hy-
pometabolism in posterior cingulate, posterior precuneus,
inferior parietal cortex, lateral temporal cortex, and prefron-
tal cortex. Relative hypermetabolism was found in cere-
bellum, pons, paracentral lobule, putamen, thalamus, and
occipital subregions. The CV2FDG and CV1FDG patterns
overlapped in a portion of precuneus and posterior cingulate,
but otherwise were largely distinct (Supplementary Fig. 3).
The 5-class NPAIRS analysis of DS, NL, EMCI, LMCI,
and AD subjects provided a finer resolution comparison of
DS subjects to the AD progression spectrum. The five-class
CV1 pattern was similar to the three-class CV1FDG pattern,
differentiating DS from all other groups (P , .00001, ES
6.38) and did not differentiate non-DS groups. An AD-like
CV2 pattern showed cascade-like progression from NL to
EMCI to LMCI toAD aswe have found in ourADProgression
classifier. DS subjects scored across the spectrum from NL to
AD as in the 3-class comparison (Supplementary Fig. 4).
Confirming that theDS-associated pattern CV1FDGwas not
attributable to DS vs. ADNI subject age differences, the 4-
class NPAIRS analysis of DS, NL, AD, and AE-NL subjects
produced a CV1 pattern differentiating DS similarly from
both NL and AE-NL, highly similar to the 3-class CV1FDG
pattern. In addition, a CV2 pattern differentiated AD subjects
fromNormal groups (both ADNI and NYU), with DS subjects
expressing a spectrum of scores. Despite lower resolution due
to greater smoothing, the absence of superior slices, the CV1
and CV2 eigenimages were very similar to those produced us-
ing only ADNI comparators (Supplementary Fig. 5).
Fig. 1. Results of 3-class FDG PET NPAIRS analysis. (A) DS-specific (CV1FDG) and (B) AD-specific (differentiates AD vs NL, CV2FDG) patterns are shown
from the three-class FDG PETanalysis. The numeric scores (circles) in the graph reflects the degree towhich each subject expresses the corresponding pattern of
relative hypo (blue) and hyper (red) metabolism (higher score on y-axis corresponds to greater pattern expression). Unfilled circles indicate amyloid negative or
threshold, and filled circles indicate amyloid positive. DS subjects who were amyloid negative or at threshold as measured by florbetapir PET are shown as
unfilled circles to the left of those who were amyloid positive (filled circles). Abbreviation: FDG, fluorodeoxyglucose; PET, positron emission tomography;
DS, Down syndrome; AD, Alzheimer’s disease; NL, cognitively normal amyloid negative.
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the 4-class analysis of DS, NL, AD, and SITE1 produced a
CV1 pattern resembling the 3-class CV1FDG pattern and
differentiating DS from NL, AD, and SITE1 (all
P , .00001, Supplementary Fig. 6), which were not distin-
guished from one another. CV2 and CV3 patterns differenti-
ated NL and AD (P , .00001, P , .0001), with DS and
SITE1 subjects distributed in expression.
The 2-class analysis comparing DS and NL subjects was
constrained to identify only one pattern. This pattern differ-
entiated DS and NL and incorporated elements from both
CV1FDG and CV2FDG. Similar to published studies, contri-
butions of DS and AD could not be dissociated
(Supplementary Fig. 7).3.3. FDG AD progression classifier scores
DS AD Progression scores (Fig. 2A) ranged from values
typical of Am2 NL subjects to those of AD subjects estab-
lished through previous independent testing of ADNIFig. 2. Comparison of FDGAD progression classifier and CV2FDG. (A) AD progre
plotted. Dotted lines show mean AD progression scores of independently teste
(NL 5 cognitively normal amyloid negative, EMCI 5 early MCI, LMCI 5 late
FDG AD progression scores; (C) FDG PET AD progression classifier patter
Red5 relative hyper or preserved metabolism. Abbreviation: FDG, fluorodeoxygl
heimer’s disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative.subjects of known clinical diagnosis and amyloid status.
AD Progression scores increased with age (R 5 0.602,
P , .04) and with amyloid burden. All Am2 or threshold
subjects had scores reflecting less AD-like pattern expres-
sion than typical of LMCI or AD.
Shown in Fig. 2B and 2D, the CV2FDG scores correlate
with FDG AD progression scores (R 5 0.993,
P , .00001), and the pattern is highly similar to the a priori
AD progression pattern, dominated by hypometabolism in
posterior cingulate, precuneus, and inferior parietal cortices
with preservation in cerebellum, pons, paracentral lobule,
thalamus, and striatum.3.4. FDG region of interest analyses
Fig. 3A and 3B present region of interest analysis results
in PCC and IPL, referenced towhole brain, for DSAm2, DS
Am1, NL, EMCI, LMCI, and AD subjects. Fig. 3C and 3D
show the relationship between SUVR and age for DS, NL,
and AD. Consistent with the PCC hypometabolism observedssion scores of Down syndrome subjects and correlation with subject age are
d amyloid-characterized subjects from the ADNI database as references
MCI); (B) Relationship between three-class FDG PET CV2FDG scores and
n (eigenimage); (D) CV2FDG pattern. Blue 5 relative hypometabolism,
ucose; PET, positron emission tomography; DS, Down syndrome; AD, Alz-
Fig. 3. FDG PET region of interest results. The posterior cingulate-precuneus (A) and inferior parietal cortex (B) region of interest SUVR values are shown, normal-
ized towhole brain, for DS Am2, DS Am1, NL Am2, EMCI Am1, LMCIAm1, and ADAm1 subjects. Asterisks indicate nonparametric comparison test (Wil-
coxon2Mann2Whitney) significance levels (*P, .05, **P, .005, tr5 trend).P, .005 remained significant after Bonferroni correction for multiple comparisons.
In c and d, relationships between regional SUVR values and age are shown for DS, NL (green diamonds), and AD subjects (red triangles). For the DS subjects in
(C) and (D), unfilled circles are amyloid negative or threshold, and filled circles are amyloid positive. Abbreviation: FDG, fluorodeoxyglucose; PET, positron emis-
sion tomography; DS, Down syndrome; NL 5 cognitively normal amyloid negative, EMCI, early MCI; LMCI, late MCI; AD, Alzheimer’s disease.
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both DS Am2 and DS Am1 (both P , .005) subjects and
decreased with age. In contrast, DS Am2 subjects did not
differ from NL in IPL, whereas DS Am1 showed an age-
associated trajectory toward LMCI and AD levels. Consis-
tent with NPAIRS results, hypometabolism was also
measured in Hippocampus. Results were consistent when
comparing to AE-NLs and when using pons as a compara-
tive reference region (Supplementary Table 1).3.5. Correlation between PET markers and cognitive/
functional measures
Fig. 4 shows example correlation plots between clinical
endpoints and CV2FDG scores (4a) and amyloid SUVR(4b) in DS subjects. CV2FDG score correlates with
several baseline measures including Observer
Memory Questionnaire-Parent Form (OMQ-PF [44],
R 5 20.776, P , .003), attention (R 5 20.776,
P , .003), daily living skills (R 5 20.690, P , .01), total
memory (R 5 20.627, P , .03), and CAMCOG total er-
rors (R 5 0.595, P , .04), and at trend level with CAM-
COG total score 2 (composite of orientation, language,
remote memory, recent memory, attention, abstraction,
perception, R 5 20.524, P , .08; Fig. 4A). CV1FDG cor-
relates with baseline Communication score (R 5 20.680,
P , .02). In contrast, although Am2 status corresponds to
better cognitive and functional scores than Am1 status
and reaches significance for OMQ-PF (R 5 20.680,
P , .02), there is no correlation between amyloid
Fig. 4. Correlations between FDG and amyloid PET measures and clinical data. (A) CV2FDG score in DS subjects vs cognitive and functional measures at
baseline, and (B) Amyloid SUVR in DS subjects vs cognitive and functional measures at baseline. The FDG values correlate with clinical endpoints throughout
the spectrum of scores. In contrast, although there is a general correlation between amyloid negative vs amyloid positive status and clinical endpoints, the cor-
relation no longer holds within the amyloid positive subgroups (second set of dotted lines). Spearman’s R values are shown.
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(Fig. 4B).3.6. Structural MRI results
Fig. 5 illustrates results from the 3-class NPAIRS analysis
of modulated gray MRI segments of DS, NL, and AD, which
produced two CVs. The first CV (Fig. 5A, CV1sMRI) differ-
entiated DS from NL (P , .00001, ES 3.55) and AD
(P , .00001, ES 4.87), and also contributed to discrimina-
tion between NL and AD (P , .00002, ES 2.09) (Wil-
coxon–Mann–Whitney tests). This pattern shows DS
volume reductions in cerebellum, occipital cortex, hippo-
campus, mid-cingulate, anterior cingulate, and temporal cor-
tex. Preserved or increased volume was found in DS in
caudate, putamen, thalamus, inferior lateral temporal cortex,
inferior parietal cortex, and prefrontal cortex compared to
NL and AD. AD scores were lower than NL, to interpret
in combination with the second pattern (Fig. 5B, CV2sMRI).
CV2sMRI differentiated NL from AD (P , .003, ES 1.65),
whereas DS scores distributed across the range from NL to
AD. This pattern showed volume reductions in posteriorcingulate, precuneus, parietal cortex, hippocampus, tempo-
ral cortex, frontal cortex, and caudate, with preserved or
increased volume in putamen, thalamus, and midbrain. Vol-
ume reductions were consistent with AD-like atrophy.
As in CV1FDG, there is no association between CV1sMRI
score and amyloid status or age in DS subjects. As in
CV2FDG, four of six subjects with the lowest CV2sMRI scores
are Am2 or threshold.
As a caveat, some scans had motion artifact that intro-
duced noise into the analyses. One scan was excluded
from analyses in Figs. 4 and 5 due to blur. Three Am1 DS
subjects showed notable ventricular enlargement. In
addition, whereas DS scans were acquired on a 1.5 T
scanner and ADNI comparator scans came from a
combination of 1.5 T and 3 T scanners, no resolution-
related patterns were identified using the smoothed gray
matter segments.
The DS sMRI CV scores showed somewhat weaker rela-
tionships with clinical measures than FDG CV scores.
CV2sMRI scores correlate with OMQ-PF (R 5 20.718,
P , .01, Fig. 5E), Attention (R 5 20.636, P , .04), Total
Memory (R 5 20.573, P , .06, trend), and Daily Living
Fig. 5. Structural MRI analysis results. (A) Down syndrome associated pattern (CV1sMRI) and (B) AD associated pattern derived from the three-class MRI
NPAIRS analysis. The numeric score for each subject (circle) reflects the degree to which they express the corresponding pattern of relatively lower volume
(blue) and greater volume (red). A higher y-axis score corresponds to greater pattern expression. Unfilled circles 5 amyloid negative, filled
circles5 amyloid positive. DS subjects whowere amyloid negative or threshold are shown as unfilled circles to the left of the DS Am1 subjects (filled circles).
Both patterns contain elements that combine to differentiate NL and AD. (C)–(E) show correlations (Spearman’s R values) between CV2sMRI scores vs CV2FDG
scores, FDG AD progression scores, and OMQ-PF score, respectively.
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were not found between CV1sMRI scores and clinical
measures.3.7. Conjunction of functional and structural results
The CV2sMRI score correlates with CV2FDG (R 5 0.745,
P , .008; Fig. 5C) and AD Progression Score (R 5 0.736,
P , .01; Fig. 5D). Common regions between CV1FDG and
CV1sMRI include relative hypometabolism and volume
reduction in mid-cingulate, anterior cingulate, paracentral
lobule, and hippocampus; relative hypermetabolism andvolume preservation in prefrontal cortex; and relative hyper-
metabolism but volume reduction in occipital cortex. Com-
mon regions between CV2FDG and CV2sMRI include relative
hypometabolism and reduced volume in posterior cingulate,
precuneus, inferior parietal cortex, and hippocampus; and
relative hypermetabolism and volume preservation in puta-
men and thalamus.
There were some differences between the FDG and
sMRI findings. Cerebellar volume reduction was seen in
DS compared to NL and AD, but metabolic differences
were subtle. Volume preservation in thalamus, striatum,
and lateral inferior temporal cortex was found in DS
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observed within FDG-CV1. Medial frontal hypermetabo-
lism was found in DS relative to NL and AD but without
volumetric preservation.4. Discussion
In this study, while on a preliminary basis given the small
sample size and other limitations, we have demonstrated the
dissociation of functional and structural effects associated
with adult DS independent of a positive amyloid PET scan
from those associated with prodromal AD within Am1 sub-
jects. Results also show that the degree of Alzheimer’s-type
neurodegeneration, reflected in FDG and MRI biomarkers,
can be quantified in nondemented DS subjects. AD pattern
expression varies greatly within the Am1 DS subjects as
do clinical manifestations, underscoring the importance of
characterization. We have also shown that FDG and MRI
CV scores correlate with cognitive and functional endpoints,
whereas amyloid burden does not within the Am1 DS sub-
group.
The DS-associated CV1FDG pattern hypometabolism
partially overlapped but was distinct from the AD-like
CV2FDG pattern. Hypometabolism in paracentral lobule
and striatum and prominent anterior cingulate and inferior
frontal regions differed from core AD features. The mid-
and anterior cingulate regions of CV1FDG have been asso-
ciated with motor activation, error detection, and emotion
[45]. Of interest is the posterior cingulate-precuneus hypo-
metabolism in all DS subjects in NPAIRS and ROI results,
significantly lower than NL and also EMCI Am1 subjects
even in DS subjects negative for amyloid burden.
Decreased posterior cingulate metabolism has been found
in asymptomatic APOE ε4 carriers [8] and in some subjects
with decreasing Abeta CSF but negative amyloid PET. As
two of three Am2 subjects and the threshold Am DS sub-
ject were not APOE ε4 carriers, the hypometabolism could
potentially arise from trisomy-driven abnormal amyloid
turnover resulting in excess accumulation of Abeta rather
than APOE ε4 effects or another mechanism. We note
that all subjects had positive retinal amyloid measures
[3]. Similar hypometabolism was seen in hippocampus in
the NPAIRS and region of interest results when referenced
to pons. Study of subjects in their 20’s could enable inves-
tigation of the point at which hypometabolism in these re-
gions begins to appear.
The relative frontal hypermetabolism within CV1FDG
was consistent with reports of regional hypermetabolism in
young DS subjects. Such studies have hypothesized
compensatory activity in response to deficient neural net-
works [12,13,15,46] and/or a lower effectiveness of
glycolysis related to downregulation of phosphoglucose
isomerase, elevating glucose-6-phosphate [13].
The AD-like FDG pattern (CV2FDG) is consistent
with our FDG AD progression pattern and AD literature,
supporting AD-relevance, and robustness despite smallsample size. As in ADNI subjects, the AD-like pattern in
DS subjects correlates with clinical endpoints. The pres-
ence of AD-like effects in nondemented DS is consistent
with findings of an AD-like pattern in older nondemented
DS by Azari [47]. The posterior cingulate hypometabolism
in this pattern was consistent with findings by Sabbagh et al
in both nondemented and demented DS, correlating with
increasing age and dementia [17].
DS-specific pattern CV1sMRI is consistent with reports of
reduced cerebellar, cingulate, and hippocampal volume but
preserved or increased subcortical volume, whereas
CV2sMRI was consistent with AD-related atrophy. As
CV1sMRI also captured differences between NL and AD,
further exploration of the relationship between the two
CVs is merited.
FDG and sMRI findings showed similarities and differ-
ences in the patterns differentiating DS from normals. Of
note is the cerebellum, involved in motor and postural
control, affected in DS [48]. Despite reduced cerebellar
volume in DS compared to NL, cerebellar hypometabo-
lism was subtle. Relevant DS murine model work has
found that despite reduced volume and cell density, there
were no synaptic plasticity deficits to which motor deficits
could be attributed [48]. Our findings suggest that
structural and functional imaging information may be
complementary.
There were limitations to this pilot study, particularly in
the small sample size. The NPAIRS software aided in ad-
dressing this through its segregation of signal from back-
ground noise and prevention of model over-fitting
through iterative resampling. However, additional subjects
will be important for confirmation and further pattern char-
acterization. Although the sourcing of DS subjects from a
single site (UCSD) and the primary ADNI comparators
from multiple other sites was another potential limitation,
analyses specifically comparing ADNI subjects from the
DS site showed no site-specific differences. Although age
differences were also a limitation, the consistency of
NPAIRS results obtained when age-matched NYU subjects
were included, and when explicitly comparing ROIs be-
tween DS subjects and nearly identically age-matched
NL-AE subjects, suggests that patterns were not due to
age differences. Related to age, although no age correlation
was observed in the DS-specific CV1 patterns, the youngest
subject in this study was aged 32 years. Studying adults in
their late teens and twenties may help to resolve the contrast
between hypometabolism observed in our subjects and the
hypermetabolism-only findings of some studies in young
subjects, by filling this data gap. The cross-sectional study
paradigm was also a limitation, partially offset by inclusion
of multiple comparator classes with progressive stages of
disease severity and our observation of consistent longitu-
dinal increases in AD progression pattern expression in
Am1 ADNI subjects. Longitudinal data anticipated
through studies such as DSBI and the Neurodegeneration
in Aging Down Syndrome study (NiAD) could help to
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ported if CV2 AD-like patterns are increasingly expressed
in Am1 DS subjects over time, whereas the DS related
CV1 patterns remain stable. Despite these various con-
straints, several elements support the validity of our find-
ings, including the reproducibility and prediction metrics
generated by NPAIRS, the alignment of AD-like pattern
expression with amyloid positivity, the high correlation be-
tween AD-like pattern expression and relevant clinical
measures, and consistency with published data from other
studies.
The ability to dissociate functional and structural effects
arising from AD vs underlying DS phenomena and to quan-
tify degree of AD progression may enable identification of
subjects likely to progress within a trial and detection of
disease-specific treatment response. These capabilities could
significantly enhance the viability of clinical trials of AD-
targeted therapies in DS adults.Acknowledgments
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1. Systematic review: The authors reviewed the litera-
ture using PubMed and meeting abstracts. Relevant
studies inclusive of early imaging research through
current year work were incorporated into back-
ground preparation and are appropriately cited.
2. Interpretation: Our findings led to new insights disso-
ciating and quantifying the glucose metabolic and
volumetric effects of Down syndrome and Alz-
heimer’s disease within the same subjects and their
relationship to amyloid burden and clinical status.
3. Future directions: The article lays groundwork for
expanded studies to understand the contributions of
DS and AD to clinical phenotype and to evaluate
disease-specific interventional effects. Additional
work could include the following: the study of a
larger number of DS subjects to confirm results; the
study of DS subjects from late teens through late
twenties to identify potential changes occurring in
earliest adulthood; longitudinal evaluation to identify
AD-related changes differentiable from DS effects.
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